Passive antibody therapies: Progress and continuing challenges

被引:59
作者
Casadevall, A
机构
[1] Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
关键词
monoclonal antibody; immunotherapy; serum therapy;
D O I
10.1006/clim.1999.4768
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In recent years antibody-based therapies have returned as first-line therapy for a variety of diverse conditions that include viral infections, inflammatory disorders, and certain malignancies. Renewed interest in antibody-based therapies is a consequence of major advances in the technology of antibody production and the need for new therapeutic agents. Dozens of antibody preparations are in clinical use. Several monoclonal antibodies are now licensed for clinical use and many are in advanced clinical development. Antibody-based therapies have both significant advantages and disadvantages relative to conventional chemotherapy. Advantages include versatility, specificity, and biological functions not replicated by available chemotherapeutic drugs. Disadvantages include high cost and small markets that hinder commercial development. The available experience suggests that antibody-based therapies can be successfully developed for use in clinical situations where no effective therapy is available. Continued success in the development of antibody-based therapies will require extensive clinical research to learn how to use these compounds optimally and basic immunological research to define the basic mechanisms of antibody action. (C) 1999 Academic Press.
引用
收藏
页码:5 / 15
页数:11
相关论文
共 86 条
  • [21] Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
    Goldenberg, MM
    [J]. CLINICAL THERAPEUTICS, 1999, 21 (02) : 309 - 318
  • [22] GOOD RA, 1991, CANCER, V68, P1415, DOI 10.1002/1097-0142(19910915)68:6+<1415::AID-CNCR2820681402>3.0.CO
  • [23] 2-0
  • [24] GOODRICK J, 1994, CLIN EXP IMMUNOL, V98, P17
  • [25] Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection
    Hale, G
    Zhang, MJ
    Bunjes, D
    Prentice, HG
    Spence, D
    Horowitz, MM
    Barrett, AJ
    Waldmann, H
    [J]. BLOOD, 1998, 92 (12) : 4581 - 4590
  • [26] Hank JA, 1995, CLIN CANCER RES, V1, P481
  • [27] Antibody engineering
    Hayden, MS
    Gilliland, LK
    Ledbetter, JA
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (02) : 201 - 212
  • [28] Experience with the use of an investigational F(ab')(2) heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt
    Hibbs, RG
    Weber, JT
    Corwin, A
    Allos, BM
    ElRehim, MSA
    ElSharkawy, S
    Sarn, JE
    McKee, KT
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (02) : 337 - 340
  • [29] Jahrling PB, 1996, ARCH VIROL, P135
  • [30] KANG A S, 1991, Methods (Orlando), V2, P111, DOI 10.1016/S1046-2023(05)80211-7